uniQure NV (LTS:0EE0)
$ 16.2348 0.9948 (6.53%) Market Cap: 762.83 Mil Enterprise Value: 395.19 Mil PE Ratio: 0 PB Ratio: 14.23 GF Score: 63/100

Uniqure NV at Barclays Virtual Gene Editing & Gene Therapy Summit Transcript

Nov 16, 2020 / 07:30PM GMT
Release Date Price: $43.24
Huidong Wang
Barclays Bank PLC, Research Division - Research Analyst

Hello, everyone. My name is Gena Wang, SMID cap biotech analyst at Barclays. It is my great pleasure to introduce our next presenting company, uniQure. With me on the screen is Matt Kapusta, Chief Executive Officer from uniQure. Matt, do you want to kick off with a brief introduction about -- overview about uniQure?

Matthew Craig Kapusta
uniQure N.V. - CEO, CFO & Executive Director

Yes. Sure. Well, first, Gena, thank you for having us here at the conference. We're delighted to see you over video. So I'm Matt Kapusta, Chief Executive Officer of uniQure. So at a high level, uniQure is one of the leading pioneers in the exciting field of genetic medicine. The company was founded in 1998 and was the sponsor of the first approved gene therapy in the western world, which is a product called Glybera. That was approved in Europe for the treatment of lipoprotein lipase deficiency in 2012.

And what I think this opportunity afforded us beyond the experience of bringing a highly innovative

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot